-
Innovation Ranking
NewInnovation Ranking – ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc (ANI) is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals. The company offers pharmaceuticals for central nervous system (CNS) disorders, gastrointestinal, cancer, ophthalmic, metabolic and other diseases. ANI also conducts business as a Contract Development and Manufacturing Organization (CDMO) supporting late-stage development to commercial manufacture of pharmaceutical products including coated/non-coated tablets and capsules, ointments, creams, non-sterile liquids, suspensions, and gels. It markets oncology products, complex formulations, hormones and steroids and controlled...
-
Company Insights
Innovation and Patenting activity of ANI Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ANI Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Thematic Analysis
NewEnterprise Security Software Sector Scorecard, Q1 2024 Update – Thematic Intelligence
Artificial intelligence (AI) is a double-edged sword in cybersecurity. It can help organizations improve their threat detection, hunting, and incident response capabilities, but adversaries can and will use AI in cyberattacks. There is every likelihood that AI will spur new merger and acquisition (M&A) deals in cybersecurity, especially of companies judged to be AI specialists. In the thematic screen of GlobalData’s enterprise security software sector scorecard, AI has a weighting of 20%, higher than any other theme.
-
Thematic Analysis
NewMedia M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Media Sector. The media M&A market in Q1 2024 witnessed deals worth $33 billion, an increase of 16% compared to Q1 2023. In terms of deal volume, there was a 8% fall from 432 deals in Q1 2023 to 397 M&A deals in Q1 2024. This year recorded 11 mega deals (defined as any deal valued at or more than $1 billion), 267% increase...
-
Thematic Analysis
NewTech, Media and Telecom (TMT) M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the TMT Sector. The TMT M&A market in Q1 2024 witnessed deals worth $186 billion, a growth of 44% compared to Q1 2023. In terms of deal volume, there was an 11% fall from 2,419 deals in Q1 2023 to 2,163 M&A deals in Q1 2024. This year recorded 42 mega deals (defined as any deal valued at or more than $1 billion), 83% growth...
-
Sector Analysis
NewStretchers and Cots Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Stretchers and Cots Market Report Overview The stretchers and cots market was valued at $1.04 billion in 2023 and will grow at a CAGR of more than 2% during 2023-2033. Stretchers and cots support overall patient care and safety, irrespective of the cause of their hospital visits. They form the equipment base of all healthcare facilities in any country. For any kind of treatment to be successful, the hospital must be equipped with basic supplies such as transport stretchers, emergency...
-
Product Insights
NewLikelihood of Approval Analysis for Poisoning
Overview How likely is it that the drugs in Poisoning will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Poisoning Overview A poison refers to any substance harmful to the body, whether...
-
Product Insights
NewLikelihood of Approval Analysis for Swine Influenza
Overview How likely is it that the drugs in Swine Influenza will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Swine Influenza Overview Swine influenza is an infection caused by any of...
-
Sector Analysis
NewGeneral Hospital Supplies Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
General Hospital Supplies Market Report Overview The general hospital supplies market size was $12.7 billion in 2023. Factors such as the solid awareness about ensuring medical facilities will drive the market growth at a CAGR of more than 2% from 2023 to 2033. General hospital supplies support patient care and safety irrespective of the reason they might be visiting the hospital. General hospital supplies form the equipment base of all healthcare facilities in any country. For any kind of treatment...
-
Product Insights
NewLikelihood of Approval Analysis for Mesenchymal Tumor
Overview How likely is it that the drugs in Mesenchymal Tumor will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mesenchymal Tumor Overview Mesenchymal tumors are tumors developing from mesenchymal tissues. These...